Study guide

12.1 Psychosocial Assessment & Distress Screening in Oncology

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

12.1 Psychosocial Assessment & Distress Screening in Oncology

Key Takeaways Explain This Topic AI

The NCCN Distress Thermometer (DT) is a validated 0–10 self-report screening tool paired with a 39-item Problem List; a cutoff score of ≥4 indicates clinically significant distress requiring immediate interdisciplinary evaluation.

Routine distress screening is mandated by the Commission on Cancer (CoC) and NCCN at critical transitional points: initial diagnosis, initiation of new treatment, disease recurrence, and transition to survivorship or end-of-life care.

Validated diagnostic and mood screening tools include the Patient Health Questionnaire-9 (PHQ-9) for depression (score ≥10 indicates moderate-to-severe depression) and the Generalized Anxiety Disorder-7 (GAD-7) scale for anxiety disorders.

Accurate differential diagnosis between major depressive disorder, adjustment disorder with depressed mood, cancer-related fatigue, and hypoactive delirium is essential to prevent psychiatric mislabeling and ensure targeted interventions.

Urgent psychiatric crisis evaluation and safety protocols must be initiated immediately for patients demonstrating active suicidal ideation, severe post-traumatic stress reactions, or acute organic psychosis.

Last updated: August 2026

Psychosocial Assessment & Distress Screening in Oncology

Psychosocial distress is an unpleasant experience of a mental, physical, social, or spiritual nature that impacts an individual's ability to cope effectively with cancer, its physical symptoms, and its treatment. Psychological distress exists along a continuum, ranging from common normal feelings of vulnerability, sadness, and fear to disabling psychiatric conditions such as major depressive disorder, severe generalized anxiety, panic disorder, and existential crisis. Approximately 35% to 45% of oncology patients experience clinically significant distress during their cancer continuum. For Advanced Practice Registered Nurses (APRNs), implementing systematic, evidence-based distress screening protocols and managing psychiatric comorbidities are essential to optimizing quality of life, treatment adherence, and overall survival.

1. NCCN Distress Thermometer & Problem List

The National Comprehensive Cancer Network (NCCN) established distress as the "6th vital sign" in oncology care. The NCCN Distress Thermometer (DT) is a validated, rapid self-report screening tool featuring a visual analog scale ranging from 0 ("No distress") to 10 ("Extreme distress").

Structure of the NCCN Distress Tool

Distress Thermometer Rating : The patient reports their overall level of distress experienced over the past 7 days on the 0–10 scale.

The 39-Item Problem List : Accompanies the thermometer, allowing patients to identify specific sources of distress across five primary domains:

Practical Problems : Housing, insurance/financial, transportation, childcare, work/school.

Family Problems : Dealing with partner/children, ability to have children, family health issues.

Emotional Problems : Worry, sadness, anxiety, fear, loss of interest in usual activities, spiritual/existential distress.

Spiritual/Religious Concerns : Loss of faith, crisis of meaning, conflict with religious beliefs.

Physical Problems : Pain, fatigue, nausea, sleep disturbances, memory/concentration, mobility, bowel/bladder changes.

Clinical Cutoff Scores & Triage

DT Score 0 to 3 (Mild Distress) : Managed with primary oncology team support, psychoeducation, and routine re-screening.

DT Score ≥4 (Clinically Significant Distress) : Represents the evidence-based threshold for mandatory clinical evaluation and targeted interdisciplinary referral. A score of 4 or higher correlates with substantial functional impairment, reduced treatment compliance, and psychiatric co-morbidity.

2. Screening Frequency & Regulatory Standards

The Commission on Cancer (CoC) of the American College of Surgeons (Standard 5.2) mandates that accredited cancer centers perform routine, documented distress screening for oncology patients using a validated tool.

Key Transitional Screening Intervals

Psychosocial distress fluctuates dramatically across the disease trajectory. Screening must be performed at minimum during these critical clinical transition points:

Initial Diagnosis : Baseline assessment prior to treatment initiation.

Treatment Transitions : Start of chemotherapy, radiation therapy, or surgical intervention; switching treatment regimens due to disease progression or toxicity.

End of Primary Treatment : Transition into post-treatment survivorship care.

Disease Recurrence / Metastatic Progression : Re-evaluating psychological coping when treatment intent shifts to palliative care.

Surveillances & Follow-Up : Routine intervals (e.g., every 3 to 6 months) during ongoing therapy or survivorship.

3. Validated Psychosocial & Mood Assessment Tools

When the initial DT score is elevated (≥4) or emotional concerns are identified, the APRN should administer targeted, validated diagnostic screening instruments:

Screening Tool Target Domain Items & Scoring Clinical Cutoff & Action

NCCN Distress Thermometer (DT) Global Psychosocial Distress 1 visual analog item (0–10) + 39-item Problem List Score ≥4 : Triggers mandatory interdisciplinary referral matching problem list.

Patient Health Questionnaire-9 (PHQ-9) Depressive Symptoms & Severity 9 items scored 0–3 (Total score 0–27) 0–4 : Minimal; 5–9 : Mild; 10–14 : Moderate; 15–19 : Moderately severe; ≥20 : Severe. Score ≥10 warrants psychiatric/pharmacologic intervention. Item 9 assesses self-harm.

Generalized Anxiety Disorder-7 (GAD-7) Anxiety Symptom Severity 7 items scored 0–3 (Total score 0–21) 5–9 : Mild; 10–14 : Moderate; ≥15 : Severe anxiety. Score ≥10 indicates probable GAD; triggers psychiatric referral or pharmacotherapy.

Hospital Anxiety and Depression Scale (HADS) Anxiety & Depression in Medically Ill 14 items (7 Anxiety, 7 Depression) excluding somatic complaints 8–10 : Doubtful case; ≥11 : Definite clinical case for anxiety or depression subscale. Ignores somatic symptoms (fatigue, weight loss) caused by cancer.

4. Differential Diagnosis of Mood & Cognitive Disorders

Disentangling primary psychiatric disorders from cancer-related somatic symptoms, medication toxicities, and metabolic derangements is one of the most challenging APRN competencies.

Diagnostic Distinctions

Major Depressive Disorder (MDD) vs. Cancer-Related Fatigue (CRF) :

Cancer-Related Fatigue : Predominantly physical exhaustion, low energy, and sluggishness. Anhedonia (inability to experience pleasure) and feelings of worthlessness/excessive guilt are absent.

MDD : Core psychological symptoms of pervasive anhedonia , persistent depressed mood, hopelessness, guilt, worthlessness, and suicidal ideation are present regardless of physical energy levels.

Adjustment Disorder with Depressed/Anxious Mood :

Development of emotional or behavioral symptoms in response to an identifiable stressor (e.g., cancer diagnosis) within 3 months of stressor onset. Distress is out of proportion to the severity of the stressor or results in significant functional impairment, but does not meet full DSM-5 criteria for MDD.

Hypoactive Delirium vs. Severe Depression :

Hypoactive Delirium : Acute onset, fluctuating course, inattention , altered consciousness, cognitive disorientation, disorganized thinking. Often caused by hypercalcemia, sepsis, opioids, or brain metastases.

Depression : Insidious onset, stable course, intact attention and orientation, conscious self-awareness.

Organic & Treatment-Induced Causes of Psychiatric Symptoms :

Corticosteroids (dexamethasone/prednisone): Can induce steroid psychosis, mania, severe insomnia, or depression.

Endocrine therapies (tamoxifen, aromatase inhibitors, ADT): Can trigger mood lability and depressive symptoms.

Metabolic derangements: Hypothyroidism, hypercalcemia, hyponatremia, vitamin B12 deficiency.

5. Interdisciplinary Referral & Psychiatric Crisis Protocols

Following distress screening, the APRN mobilizes appropriate interdisciplinary team members based on the specific problem domains flagged:

Social Work : Financial toxicity, housing, transportation, community resources, insurance navigation.

Psycho-Oncology / Clinical Psychology : Psychotherapy (Cognitive Behavioral Therapy [CBT], Acceptance and Commitment Therapy [ACT]), coping strategies, fear of recurrence.

Psychiatry / Psychiatric Mental Health NP : Psychopharmacologic management of severe depression, anxiety, organic mood disorders, or psychosis.

Chaplaincy / Spiritual Care : Existential distress, crisis of faith, spiritual distress, end-of-life reconciliation.

APRN Management of Acute Psychiatric Crisis (Suicidality)

Item 9 on PHQ-9 Positive or Active Suicidal Ideation : Immediately evaluate intent, plan, and means.

Safety Protocol : Do not leave the patient unattended. Remove potentially lethal items. Conduct a formal suicide risk assessment (e.g., Columbia-Suicide Severity Rating Scale [C-SSRS]).

Immediate Intervention : Arrange urgent psychiatric consultation or emergency department transfer for involuntary hold/inpatient psychiatric stabilization if high risk/active plan is present.

Loading diagram... NCCN Distress Screening, Triage & Referral Workflow